PhotoPharmics, a leader in phototherapy for neurodegenerative diseases, has announced the enrollment of the first 100 participants in its Light for PD clinical trial. This milestone is a key step in assessing Celeste, the company’s FDA Breakthrough light therapy device…
Nucleus Biologics, The Cell Performance Company™, a top provider of custom cell culture media and buffers for the cell and gene therapy sector, is excited to introduce its new QuickStart Media™ platform. This innovative platform accelerates the formulation and manufacturing…
Verastem Oncology, a biopharmaceutical firm dedicated to developing new cancer treatments, has provided an update on its business activities and financial performance for the second quarter ended June 30, 2024. Dan Paterson, the company’s President and CEO, highlighted significant advancements:…
Pulse Biosciences, Inc. (Nasdaq: PLSE) has announced that it successfully treated the first two patients in its initial human feasibility study using its innovative Cardiac Surgery System. This study, which employs the company’s proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology,…
According to a new quarterly revenue cycle benchmarking report from Kodiak Solutions, health insurers are increasingly using requests for additional information to initially deny claims from hospitals, health systems, and medical practices. This practice is leading to significant delays in…
Apyx Medical Corporation (NASDAQ: APYX), the maker of the Renuvion® helium plasma and radiofrequency platform, has announced a peer-reviewed article in Plastic and Reconstructive Surgery—Global Open. The study compares Renuvion’s Helium Plasma Technology with InMode’s Bipolar RF System following liposuction…
LEAP Consulting Group, a specialized digital consultancy for the clinical laboratory sector, is thrilled to introduce a new service designed to assist CLIA-certified labs in navigating the FDA’s updated requirements under the LDT Final Rule announced in May 2024. This…
Ontrak, Inc. (NASDAQ: OTRK), a leader in AI-powered and technology-driven behavioral healthcare, today released its expected financial results for the second quarter ending June 30, 2024. These results are pending final analysis of debt classification by management. Management Commentary Brandon…
AN2 Therapeutics, Inc. (Nasdaq: ANTX), a biopharmaceutical company specializing in novel small molecule therapies from its boron chemistry platform, today announced topline results from the Phase 2 portion of the EBO-301 Phase 2/3 study. This study evaluates the efficacy of…
Phonak, a Sonova brand, is excited to introduce the new Infinio hearing aid portfolio, featuring the groundbreaking Audéo Sphere Infinio. This hearing aid is the world’s first to use a dedicated real-time AI chip specifically designed for speech-from-noise separation. Addressing…
Hims & Hers Health, Inc. (NYSE: HIMS), a leading health and wellness platform, has released its financial results for the second quarter ended June 30, 2024. The details are available in the shareholder letter posted at investors.hims.com. Hims & Hers…
Concentric Analgesics, Inc., a clinical-stage biopharmaceutical firm specializing in innovative non-opioid pain treatments, has unveiled new positive clinical data for vocacapsaicin, its leading product candidate for managing postsurgical pain. The data will be presented in a poster session at the…